 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
1qsg
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Oxidoreductase
|
 |
|
Title:
|
 |
Crystal structure of enoyl reductase inhibition by triclosan
|
|
Structure:
|
 |
Enoyl-[acyl-carrier-protein] reductase. Chain: a, b, c, d, e, f, g, h. Synonym: nadh-dependent enoyl-acp reductase. Engineered: yes
|
|
Source:
|
 |
Escherichia coli. Organism_taxid: 562. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Biol. unit:
|
 |
Tetramer (from
)
|
|
Resolution:
|
 |
|
1.75Å
|
R-factor:
|
0.172
|
R-free:
|
0.215
|
|
|
Authors:
|
 |
M.J.Stewart,S.Parikh,G.Xiao,P.J.Tonge,C.Kisker
|
Key ref:
|
 |
M.J.Stewart
et al.
(1999).
Structural basis and mechanism of enoyl reductase inhibition by triclosan.
J Mol Biol,
290,
859-865.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
21-Jun-99
|
Release date:
|
21-Jul-99
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P0AEK4
(FABI_ECOLI) -
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
|
|
|
|
Seq: Struc:
|
 |
 |
 |
262 a.a.
258 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.1.3.1.9
- Enoyl-[acyl-carrier-protein] reductase (NADH).
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Acyl-[acyl-carrier-protein] + NAD+ = trans-2,3-dehydroacyl-[acyl- carrier-protein] + NADH
|
 |
 |
 |
 |
 |
Acyl-[acyl-carrier-protein]
|
+
|
NAD(+)
Bound ligand (Het Group name = )
corresponds exactly
|
=
|
trans-2,3-dehydroacyl-[acyl- carrier-protein]
|
+
|
NADH
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
1 term
|
 |
|
Biological process
|
metabolic process
|
7 terms
|
 |
|
Biochemical function
|
nucleotide binding
|
3 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Mol Biol
290:859-865
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis and mechanism of enoyl reductase inhibition by triclosan.
|
|
M.J.Stewart,
S.Parikh,
G.Xiao,
P.J.Tonge,
C.Kisker.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The enoyl-acyl carrier protein reductase (ENR) is involved in bacterial fatty
acid biosynthesis and is the target of the antibacterial diazaborine compounds
and the front-line antituberculosis drug isoniazid. Recent studies suggest that
ENR is also the target for the broad-spectrum biocide triclosan. The 1.75 A
crystal structure of EnvM, the ENR from Escherichia coli, in complex with
triclosan and NADH reveals that triclosan binds specifically to EnvM. These data
provide a molecular mechanism for the antibacterial activity of triclosan and
substantiate the hypothesis that its activity results from inhibition of a
specific cellular target rather than non-specific disruption of the bacterial
cell membrane. This has important implications for the emergence of
drug-resistant bacteria, since triclosan is an additive in many personal care
products such as toothpastes, mouthwashes and soaps. Based on this structure,
rational design of triclosan derivatives is possible which might be effective
against recently identified triclosan-resistant bacterial strains.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Structure of triclosan. (a) Structure of
2,4,4′-trichloro-2′-hydroxydiphenyl ether (triclosan). (b)
F[o]−F[c] electron density omit refinement map contoured at
3Σ around the triclosan and NADH. NADH and triclosan were
omitted from the model, which was subjected to ten cycles of
maximum likelihood refinement in REFMAC.
|
 |
Figure 3.
Figure 3. The inhibitor binding site. (a) Superposition of
the triclosan and diazaborine inhibited EnvM structures. Regions
in which the polypeptide chains differ are shown in red
(triclosan inhibited form) and blue (diazaborine inhibited
form). NADH and triclosan are shown in ball-and-stick
representation. (b) Schematic drawing of triclosan-protein and
triclosan-NADH interactions. Ball-and-stick representation of
triclosan and the nicotinamide moiety of the cofactor. Hydrogen
bonds are indicated by gray dotted lines and hydrophobic
interactions by thick blue dotted lines. (c) Stereo view of the
EnvM-triclosan and EnvM-benzodiazaborine complexes. The
inhibitors and the cofactors are shown in all-bonds
representation with triclosan in red and benzodiazaborine in
blue. Residues involved in the formation of the binding pocket
are shown in ball-and-stick representation.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(1999,
290,
859-865)
copyright 1999.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
K.Maity,
T.Banerjee,
N.Prabakaran,
N.Surolia,
A.Surolia,
and
K.Suguna
(2011).
Effect of substrate binding loop mutations on the structure, kinetics, and inhibition of enoyl acyl carrier protein reductase from plasmodium falciparum.
|
| |
IUBMB Life, 63,
30-41.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.Liu,
J.E.Cummings,
K.England,
R.A.Slayden,
and
P.J.Tonge
(2011).
Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei.
|
| |
J Antimicrob Chemother, 66,
564-573.
|
 |
|
|
|
|
 |
A.Gurvitz
(2010).
Triclosan inhibition of mycobacterial InhA in Saccharomyces cerevisiae: yeast mitochondria as a novel platform for in vivo antimycolate assays.
|
| |
Lett Appl Microbiol, 50,
399-405.
|
 |
|
|
|
|
 |
H.Lu,
and
P.J.Tonge
(2010).
Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.
|
| |
Biochemistry, 49,
1281-1289.
|
 |
|
|
|
|
 |
L.Lim,
and
G.I.McFadden
(2010).
The evolution, metabolism and functions of the apicoplast.
|
| |
Philos Trans R Soc Lond B Biol Sci, 365,
749-763.
|
 |
|
|
|
|
 |
A.I.Ramos,
S.S.Braga,
and
F.A.Almeida Paz
(2009).
Triclosan.
|
| |
Acta Crystallogr C, 65,
o404-o405.
|
 |
|
|
|
|
 |
H.Lu,
K.England,
C.am Ende,
J.J.Truglio,
S.Luckner,
B.G.Reddy,
N.L.Marlenee,
S.E.Knudson,
D.L.Knudson,
R.A.Bowen,
C.Kisker,
R.A.Slayden,
and
P.J.Tonge
(2009).
Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.
|
| |
ACS Chem Biol, 4,
221-231.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.England,
C.am Ende,
H.Lu,
T.J.Sullivan,
N.L.Marlenee,
R.A.Bowen,
S.E.Knudson,
D.L.Knudson,
P.J.Tonge,
and
R.A.Slayden
(2009).
Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia.
|
| |
J Antimicrob Chemother, 64,
1052-1061.
|
 |
|
|
|
|
 |
S.R.Luckner,
C.A.Machutta,
P.J.Tonge,
and
C.Kisker
(2009).
Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.
|
| |
Structure, 17,
1004-1013.
|
 |
|
|
|
|
 |
C.W.am Ende,
S.E.Knudson,
N.Liu,
J.Childs,
T.J.Sullivan,
M.Boyne,
H.Xu,
Y.Gegina,
D.L.Knudson,
F.Johnson,
C.A.Peloquin,
R.A.Slayden,
and
P.J.Tonge
(2008).
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
|
| |
Bioorg Med Chem Lett, 18,
3029-3033.
|
 |
|
|
|
|
 |
M.Farré,
D.Asperger,
L.Kantiani,
S.González,
M.Petrovic,
and
D.Barceló
(2008).
Assessment of the acute toxicity of triclosan and methyl triclosan in wastewater based on the bioluminescence inhibition of Vibrio fischeri.
|
| |
Anal Bioanal Chem, 390,
1999-2007.
|
 |
|
|
|
|
 |
H.H.Lee,
J.Moon,
and
S.W.Suh
(2007).
Crystal structure of the Helicobacter pylori enoyl-acyl carrier protein reductase in complex with hydroxydiphenyl ether compounds, triclosan and diclosan.
|
| |
Proteins, 69,
691-694.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
K.H.Kim,
J.K.Park,
B.H.Ha,
J.H.Moon,
and
E.E.Kim
(2007).
Crystallization and preliminary X-ray crystallographic analysis of enoyl-ACP reductase III (FabL) from Bacillus subtilis.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun, 63,
246-248.
|
 |
|
|
|
|
 |
T.M.Hamill,
B.F.Gilmore,
D.S.Jones,
and
S.P.Gorman
(2007).
Strategies for the development of the urinary catheter.
|
| |
Expert Rev Med Devices, 4,
215-225.
|
 |
|
|
|
|
 |
X.He,
A.Alian,
and
P.R.Ortiz de Montellano
(2007).
Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
|
| |
Bioorg Med Chem, 15,
6649-6658.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.H.Chew,
M.Duvdevani,
and
J.D.Denstedt
(2006).
New developments in ureteral stent design, materials and coatings.
|
| |
Expert Rev Med Devices, 3,
395-403.
|
 |
|
|
|
|
 |
S.Farrell,
R.A.Baker,
M.Somogyi-Mann,
J.J.Witt,
and
R.W.Gerlach
(2006).
Oral malodor reduction by a combination of chemotherapeutical and mechanical treatments.
|
| |
Clin Oral Investig, 10,
157-163.
|
 |
|
|
|
|
 |
S.Rafi,
P.Novichenok,
S.Kolappan,
X.Zhang,
C.F.Stratton,
R.Rawat,
C.Kisker,
C.Simmerling,
and
P.J.Tonge
(2006).
Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli.
|
| |
J Biol Chem, 281,
39285-39293.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
X.He,
A.Alian,
R.Stroud,
and
P.R.Ortiz de Montellano
(2006).
Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis.
|
| |
J Med Chem, 49,
6308-6323.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.M.Zhang,
S.W.White,
and
C.O.Rock
(2006).
Inhibiting bacterial fatty acid synthesis.
|
| |
J Biol Chem, 281,
17541-17544.
|
 |
|
|
|
|
 |
J.Y.Maillard
(2005).
Antimicrobial biocides in the healthcare environment: efficacy, usage, policies, and perceived problems.
|
| |
Ther Clin Risk Manag, 1,
307-320.
|
 |
|
|
|
|
 |
S.W.White,
J.Zheng,
Y.M.Zhang,
and
Rock
(2005).
The structural biology of type II fatty acid biosynthesis.
|
| |
Annu Rev Biochem, 74,
791-831.
|
 |
|
|
|
|
 |
Y.M.Zhang,
Y.J.Lu,
and
C.O.Rock
(2004).
The reductase steps of the type II fatty acid synthase as antimicrobial targets.
|
| |
Lipids, 39,
1055-1060.
|
 |
|
|
|
|
 |
M.R.Kuo,
H.R.Morbidoni,
D.Alland,
S.F.Sneddon,
B.B.Gourlie,
M.M.Staveski,
M.Leonard,
J.S.Gregory,
A.D.Janjigian,
C.Yee,
J.M.Musser,
B.Kreiswirth,
H.Iwamoto,
R.Perozzo,
W.R.Jacobs,
J.C.Sacchettini,
and
D.A.Fidock
(2003).
Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data.
|
| |
J Biol Chem, 278,
20851-20859.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.Gilbert,
and
A.J.McBain
(2003).
Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance.
|
| |
Clin Microbiol Rev, 16,
189-208.
|
 |
|
|
|
|
 |
C.A.Bottoms,
P.E.Smith,
and
J.J.Tanner
(2002).
A structurally conserved water molecule in Rossmann dinucleotide-binding domains.
|
| |
Protein Sci, 11,
2125-2137.
|
 |
|
|
|
|
 |
H.H.Lee,
J.Yun,
J.Moon,
B.W.Han,
B.I.Lee,
J.Y.Lee,
and
S.W.Suh
(2002).
Crystallization and preliminary X-ray crystallographic analysis of enoyl-acyl carrier protein reductase from Helicobacter pylori.
|
| |
Acta Crystallogr D Biol Crystallogr, 58,
1071-1073.
|
 |
|
|
|
|
 |
J.Y.Maillard
(2002).
Bacterial target sites for biocide action.
|
| |
J Appl Microbiol, 92,
16S-27S.
|
 |
|
|
|
|
 |
K.Poole
(2002).
Mechanisms of bacterial biocide and antibiotic resistance.
|
| |
J Appl Microbiol, 92,
55S-64S.
|
 |
|
|
|
|
 |
R.Perozzo,
M.Kuo,
A.S.Sidhu,
J.T.Valiyaveettil,
R.Bittman,
W.R.Jacobs,
D.A.Fidock,
and
J.C.Sacchettini
(2002).
Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase.
|
| |
J Biol Chem, 277,
13106-13114.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Kallberg,
U.Oppermann,
H.Jörnvall,
and
B.Persson
(2002).
Short-chain dehydrogenases/reductases (SDRs).
|
| |
Eur J Biochem, 269,
4409-4417.
|
 |
|
|
|
|
 |
E.B.Martin,
L.P.Mansfield,
A.Smith,
and
S.J.Forsythe
(2001).
Inhibition of light emission from the bioluminescent bacterium Vibrio fischeri after exposure to triclosan and related hygiene care products.
|
| |
Luminescence, 16,
29-32.
|
 |
|
|
|
|
 |
H.P.Schweizer
(2001).
Triclosan: a widely used biocide and its link to antibiotics.
|
| |
FEMS Microbiol Lett, 202,
1-7.
|
 |
|
|
|
|
 |
M.P.Groziak
(2001).
Boron therapeutics on the horizon.
|
| |
Am J Ther, 8,
321-328.
|
 |
|
|
|
|
 |
R.J.Heath,
S.W.White,
and
C.O.Rock
(2001).
Lipid biosynthesis as a target for antibacterial agents.
|
| |
Prog Lipid Res, 40,
467-497.
|
 |
|
|
|
|
 |
A.W.Munro,
P.Taylor,
and
M.D.Walkinshaw
(2000).
Structures of redox enzymes.
|
| |
Curr Opin Biotechnol, 11,
369-376.
|
 |
|
|
|
|
 |
K.L.Fillgrove,
and
V.E.Anderson
(2000).
Orientation of coenzyme A substrates, nicotinamide and active site functional groups in (Di)enoyl-coenzyme A reductases.
|
| |
Biochemistry, 39,
7001-7011.
|
 |
|
|
|
|
 |
R.A.Slayden,
R.E.Lee,
and
C.E.Barry
(2000).
Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.
|
| |
Mol Microbiol, 38,
514-525.
|
 |
|
|
|
|
 |
R.J.Heath,
J.Li,
G.E.Roland,
and
C.O.Rock
(2000).
Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene.
|
| |
J Biol Chem, 275,
4654-4659.
|
 |
|
|
|
|
 |
S.L.Parikh,
G.Xiao,
and
P.J.Tonge
(2000).
Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
|
| |
Biochemistry, 39,
7645-7650.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|